About Sermorelin Field Guide

What this site is

Sermorelin Field Guide is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on sermorelin, the GHRH(1-29) growth-hormone secretagogue. We read the studies and explain what they actually measured, in everyday words, with every number tied to a source you can check.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Despite the word "shop" in the domain name, nothing here is for sale and nothing is dispensed — the name is editorial framing, not a storefront. Our work is editorial commentary on publicly available science.

Why the 'shop' name is a reading desk, not a store

The domain modifier — "shop" — is a position this publisher occupies relative to the literature, a place where you come to browse the research, not a claim that the site offers any service or product. We don't list prices, we don't take orders, and we don't point you to vendors. If you're looking to buy something, this isn't that. If you're looking to understand what the sermorelin studies found, that's exactly what these pages are for.

The regulatory history, stated straight

Sermorelin's record is often misstated, so here it is plainly. Sermorelin acetate was a genuinely FDA-approved drug — used to treat growth hormone deficiency in children — and it was withdrawn from the US market in 2008 for commercial reasons, not because of any safety or efficacy problem ^[1][5]. It is not a banned or dangerous compound; it simply stopped being sold as a branded product.

Today sermorelin is prepared through compounding pharmacies and is treated as a long-standing Category 1 bulk drug substance under the FDA's interim Section 503A policy (final guidance January 2025), meaning the FDA does not intend enforcement action against that compounding. That status is specific to sermorelin and should not be confused with other growth-hormone-axis peptides that were reviewed separately. We state this history because getting it right is part of doing the literature justice.

Our standards

Three rules govern every page. First, every quantitative claim is cited to a real study listed in our references. Second, we never give dosing instructions or medical advice — we describe what was administered to which subjects in published research, and stop there. Third, where the evidence is thin, we say so plainly rather than papering over the gap. The aging anti-aging data are limited, and we foreground the cautions instead of burying them.